Selected Non-Hodgkin's Lymphoma abstracts from the American Society of Hematology (ASH) 2009 convention in New Orleans http://ash.confex.com/ash/2009/webprogram/start.html List compiled by Greg Dafoe

Non-Hodgkin's Lymphoma Cyberfamily Home

 

Table of contents

1. Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation Poster I

2. Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster I

3. Clinical Results - Allogeneic Matched Related Donor Transplantation Poster I

4. Clinical Results - Alternative Donor Transplantation Poster I

5. Experimental Transplantation - GVHD and GVL Poster I

6. Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster I

7. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster I

8. Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster I

9. Clinical Results - Allogeneic Matched Related Donor Transplantation: Lymphoid Malignancies/Myeloma

10. Lymphoma: Chemotherapy, excluding Pre-Clinical Models - PET Therapeutic Strategies and Special Populations

11. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Uncommon Lymphomas and Supportive Care

    1. Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Clinicopathological Correlations in Non-Hodgkin Lymphoma

12. Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster II

13. Clinical Results - Allogeneic Matched Related Donor Transplantation Poster II

14. Clinical Results - Autologous Transplantation Poster II

15. Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster II

16. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II

17. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster II

18. Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster II

19. Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols

20. Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols

21. Experimental Transplantation - Basic Biology, Immune Function, and Engraftment: Insights Into Mechanisms of Stem Cell Mobilization, Homing and Expansion

22. Lymphoma: Chemotherapy, excluding Pre-Clinical Models - Non-Hodgkin Lymphoma: Therapy

23. Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Genetic Factors in Lymphoma

24. Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation: Immunology of Acute and Chronic Graft-versus-Host Disease

25. Clinical Care, Recurrence, Secondary Neoplasia and Late Complications After Transplantation II

26. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: New Targets in the Treatment of Lymphomas

27. Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Diffuse Large B-cell lymphoma: Biology and Prognosis

28. Clinical Results - Alternative Donor Transplantation II

29. Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Indolent Non-Hodgkin's Lymphoma: Biology

30. Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation Poster II

31. Clinical Results - Allogeneic Matched Related Donor Transplantation Poster III

32. Clinical Results - Autologous Transplantation Poster III

33. Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster III

34. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster III

35. Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster III

36. Clinical Results - Autologous Transplantation: Lymphoma and CLL

37. Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments

38. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Treatment of B-cell Lymphomas with Anti-CD20 Antibodies

39. Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Non-Hodgkin's Lymphoma: Biology

Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation Poster I

1132 Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation

1133 Late-Onset Hemorrhagic Cystitis in Children After Hematopoietic Stem Cell Transplantation (HSCT) for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir (CDV)

1134 Response of 864 Patients to Steroids as Primary Therapy for Acute Gvhd at a Single Institution: Day 28 Response Is the Best Endpoint to Predict Transplant-Related Mortality

1135 Elevated Serum Ferritin Predicts the Delay of Engraftment and High Incidence of Blood Stream Infection within 100 Days After Allogeneic Hematopoietic Stem Cell Transplantation

1136 High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation

1137 Immunogenicity of the Live Attenuated Varicella Vaccine Following Allogeneneic HCT

1138 MICA-129 Genotype, Soluble MICA and Anti-MICA Antibodies as Biomarkers of Chronic Graft Versus Host Disease

1139 Evaluation of NIH Consensus Criteria for Classification of Late Acute and Chronic Gvhd in Reduce Intensity Conditioning (RIC) Stem Cell Transplantation (SCT)

1140 High Dose Valacyclovir Is Highly Effective to Prevent Cytomegalovirus and Other Herpes Viruses Viremia After Allogeneic Stem Cell Transplantation

1141 Long-Term Follow-up of HCV Infected Stem Cell Transplant Patients and Effects of Antiviral Therapy

1142 Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies

1143 The Optimal Initiation Timing for Cyclosporine in Allogeneic Transplantation, Earlier Is Better with the Price of Higher Rate of Chronic Gvhd

1144 Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies –  A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience

1145 Correlations Between Host Cellular Immune Responses and Adenovirus (AdV) Associated Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation

1146 Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation

1147 Fludarabine, Cytarabine, Busulphan, and Cyclophosphamide (FABC) as Conditioning Regimen in Hematopoietic Stem Cell Transplantation for Treatment of 92 Patients with Hematologic Malignancies

1148 A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation

1149 Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age

1150 Early Detection of Isohemagglutinin From Donor Lymphocytes Has Impact On Acute Graft-Versus-Host Disease After Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation

1151 Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study

1152 Effect of KGF (Palifermin) On Immune Reconstitution After Autologous Transplantation for Multiple Myeloma

1153 Oral Beclomethasone Dipropionate Monotherapy as An Initial Treatment for Stage 1-2 Gastrointestinal Tract Acute Graft-Versus-Host Disease Following Unrelated Cord Blood Transplantation

1154 Influence of Genetic Variability of GSTM1 and GSTT1 Null Alleles Between Donor and Recipient in the Development of Acute Graft Versus Host Disease

1155 "ATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantation "

1156 Collagen and Elastin Degradation Products as Potential Biomarkers for Chronic Graft-Versus-Host Disease (cGVHD)

1157 Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) – A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT)

1158 Association Between TNF and TNF Receptor II Gene Polymorphisms and Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Haematopoietic Stem Cell Transplantation within Chinese Population

1159 Donor Inflammatory Gene Polymorphisms Are Associated with Early Bacterial  Infection After Unrelated Allogeneic Haematopoietic Stem Cell Transplantation

1160 Proportion of IL-17A Producing CD4+ Cells Increases in Response to Alloreactivity as Part of a Network Involving Memory and Regulatory Cells Post HSCT

1161 Clinical Significance of EBV-Associated LPD After Cord Blood Transplantation

1162 Clinical Characteristics and GVL Effect of Chronic Graft-Versus-Host disease Following Reduced-Intensity Umbilical Cord Blood Transplantation (RICBT)

1163 Successful High-Dose Ribavirin Treatment of Respiratory Syncytial Virus-Induced Tracheobronchitis and Pneumonia Occuring Pre-Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients

1164 Proteomic Screening Applied to the Diagnosis of Chronic Graft-Versus-Host-Disease

1165 Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients

1166 Prognostic Significance of Complement System Activation After Allogeneic Hematopoietic Stem Cell Transplantation

1167 Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd

1168 Prospective Study of Oral Valganciclovir for Pre-Emptive Therapy of Cytomegalovirus After Allogeneic Stem Cell Transplantation

1169 Influenza A H1N1 Virus Infection in Two Hematopoietic Stem Cell Transplant Recipients

1170 Identification of Low Frequency Multiple Novel Aspergillus Fumigatus Specific MHC Class II Epitopes and Rapid Generation of An Aspergillus-Specific T-Cell Product Based On Activation Dependent Expression of CD154

1171 Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies

1172 Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil Is Safe and Effective as Acute Gvhd Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Stem Cell Transplantation

1173 Thymic Recovery and De Novo T Cell Production During the First Year After Unrelated Cord Blood Transplant (UCBT) Predicts Overall Survival: A Multivariate Analysis of 93 Patients Following Myeloablative Conditioning and a Single Unit Graft

Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster I

1174 Prevalence and Significance of Pre-Formed Anti-HLA Antibodies in Hematopoietic Stem Cell Transplant Recipients

1175 Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial

1176 Nilotinib Treatment Post - Allogeneic Stem Cell Transplantation (alloSCT) in Advanced (>CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

1177 Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma

1178 Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience

1179 Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation

1180  Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO)

1181 Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

1182  Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation

1183 Engraftment Kinetics After Transplantation of Double Units of Umbilical Cord Blood From Unrelated Donors in Adolescents and Adults with Hematologic Malignancies

1184 Unpredictable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination of Optimal Once-Daily Busulfan Dose Using Pharmacokinetic Modeling

Clinical Results - Allogeneic Matched Related Donor Transplantation Poster I

1185 Impact of Missing KIR Ligands in HLA-Matched Unrelated Donor HSCT

1186 Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma

1187 Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire

1188 Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française De Greffe De Moelle-Thérapie Cellulaire (SFGM-TC)

1189 Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT)

1190 Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT

1191 TLR9 but Not NOD2/CARD15 Gene Polymorphism Influence Outcome in AML-Patients Transplanted From HLA-Identical Sibling Donors

1192 Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL)

1193 "Human Development Index" Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia

1194 A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia

Clinical Results - Alternative Donor Transplantation Poster I

1195 "An Intention-to-Treat Analysis of Rome Transplant Network Policy for Alternative Donor Search in Patients Lacking a HLA Matched Related donor"

1196 Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation

1197 Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies

1198 Unrelated Cord Blood Transplantation (UCBT) in Adults with MDS or Secondary Acute Myeloblastic Leukemia (sAML): a Survey On Behalf of Eurocord and CLWP of EBMT

1199 Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation

1200 The Prognostic Value of Residual FDG-Avidity Prior to Allogeneic Stem Cell Transplantation for Lymphoma

1201 Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma

1202  Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

1203 Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution

1204 Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma

1205 A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC 

1206 The Impact of HLA Haplotype Matching for Mismatched Cord Blood Transplantation

1207 Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin,  with or without " 2Gy TBI, for Alternative Donor Transplants in Acquired Aplastic Anemia (SAA): A Report From the EBMT-SAA Working Party

1208 Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Outcomes Are Not Impaired in Patients of Advanced Age

1209 Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation

1210 Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia

1211 Unrelated Cord Blood Transplantation in Patients with Hematologic Malignancies in Brazil – A Sociedade Brasileira De Transplantes De Medula Ossea and Eurocord Collaborative Study

1212 Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation

Experimental Transplantation - GVHD and GVL Poster I

1329 Quantification of WT1 Gene Expression for Minimal Residual Disease Detection as Predictor of Relapse in Patients with AML After Allogeneic Stem Cell Transplantation Compared to Flow Cytometry and Chimerism

1330 Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia

1331 Donor BM Dendritic Cells Expressing IDO Limit Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplant

1332 Memory CD8+ T Cells Specific for Minor Histocompatibility Antigen H60 Can Mediate the Graft-Versus-Leukemia Effect

1333 Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4+ Cytotoxic T Cells

1334 Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells

1335 P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Regulates Experimental Graft-Versus-Host-Disease

1336 ATP Acts as Danger Associated Molecular Pattern and Enhances Acute Graft-Versus-Host Disease Severity Via P2X7-R

1337 CCR1 Is Required for Treg-Mediated Protection From Lethal Acute Graft-Versus-Host Disease

1338 Galectin-9 Ameriorates Acute GVHD by Inducing T-Cell Apoptosis and Increasing Regulatory T Cell

1339 Activation of the Adenosine A2A Receptor Promotes the Development of Donor-Derived T Regulatory Cells in a Graft-Versus Host Disease Mouse Model

1340 Adoptive Transfer of Primed T Cells Mediates a Graft-Versus-Leukemia Effect against Pediatric ALL

1341 Regulatory T Cells Prevent Effector T Cell Infiltration Into GvHD Target Tissue by Affecting Chemokine Signaling

1342 Mutual Activation and Expansion of Donor CD4+ T Cells and B Cells in Transplants Play a Critical Role in the Initiation of Chronic Graft-Versus-Host Disease

1343 Hematopoietic Regeneration Is Suppressed by the GvHD Condition in a Haplo-Identical Bone Marrow Transplant Model

1344 Identification of Novel MHC Class II-Restricted Male-Specific mHAg Encoded by SMCY (JARID1D)

Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster I

1657  Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)

1658 Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

1659 Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma

1660 Aggressive Primary Chemotherapy Plus Autologous Stem Cell Transplantation Improves Outcome for Peripheral T Cell Lymphomas Compared with CHOP-Like Regimens

1661 The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL

1662 Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study

1663 Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain

1664 Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease

1665 A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma

1666  A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction of Outcome

1667 Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma

1668 Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups

1669 A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma

1670 Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin’s Disease: Mature Results of the G4 Trial

1671 Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial

1672 High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL)

1673 A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

1674 Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results

1675 Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

1676 Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin’s Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003)

1677 Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin’s Lymphoma (EXTEND):  Results From the Treatment and Follow-up Periods

1678 Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)

1679 R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

1680 Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data

1681 Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis

1682 Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

1683 Post-Renal Transplant De Novo Non-Skin Malignancies in Mycophenolate Mofetil- and Calcineurin Inhibitor-Based Immunosuppression

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster I

1700 Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

1701 Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study

1702 Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers

1703 Feasability and Toxicity After Induction Treatment with Rituximab-HCVAD and Metotrexate/Citarabine, Followed by Consolidation with Y-90 Ibritumomab Tiuxetan (Phase II GELTAMO–LCM 04-02 study)

1704 Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL)

1705 Rituximab Infusion Induces NK Activation in Subjects with the High Affinity CD16 Polymorphism

1706 Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial

1707 Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study

1708 Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma

1709 The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden

1710 The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies

1711 Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies

1712 Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

1713 Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma

1714 A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster I

1914 Increased Activity of the S Phase Kinase Cdc7 Is Associated with Poor Outcome in Diffuse Large B Cell Lymphoma (DLBCL)

1915 RNA-Expression and Proteome Analysis Identify Complementary but Not Identical Molecular Targets in Enzastaurin-Treated Mantle Cell Lymphoma

1916 Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin’s Lymphoma Development and Survival

1917 Aberrant Overexpressions of MicroRNA-21 and MicroRNA-155 Activate AKT Signaling Via Downregulation of Tumor Suppressors in NK-Cell Lymphoma/Leukemia

1918 Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies

1919 TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis

1920 Trends in Human T-Cell Leukemia Virus Type-1 (HTLV-1) Prevalence and the Incidence of Adult T-Cell Leukemia/Lymphoma (ATL) in Nagasaki, Japan: A Hospital-Based and Population-Based Study

1921 Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma

1922 Frequent Expression of MUC1, a Membrane-Associated Mucin, in Adult T-Cell Leukemia Cells

1923 Flow Cytometry Study of CD148, a Tyrosine Phosphatase Receptor, in 184 Chronic B Cell Malignancies, Reveals a High Expression in Mantle Cell and Marginal Zone Lymphomas

1924 Histopathological EXAMINATION of BONE MARROW Biopsy (BMB) IN Primary Splenic B CELL Lymphomas of Marginal-ZONE ORIGIN (PSMZL). A Reliable Substitute for Spleen Pathology?

1925 Translation Regulatory Protein 4E-Binding Protein (BP)-1 Phosphorylation Identifies Diffuse Large B Cell Lymphoma Patients with Low IPI Scores Who Experience Short Survival After Chemotherapy

1926 Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era

1927 Clinico-Pathological Characteristics of B-Cell Non Hodgkins Lymphomas Associated with Hepatitis C Virus ANRS HC13 LYMPHO-C Observational Study

1928 DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL

1929 CD137 Expression Is Enhanced in EBV-Infected T or NK Cells by Viral Protein LMP1 and Mediates Anti-Apoptotic Intracellular Signaling through NF-κB Activation

1930 Lymphopenia Predicts Survival in Peripheral T-Cell Lymphoma, Unspecified

1931 Over-Expression of IDO in NHL Results in Conversion of CD4+CD25- T Cells Into CD4+CD25+ T Cells

1932 Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin’s Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention

1933 Sequence-Based Evidence for Antigen Selection in Mantle Cell Lymphoma: Remarkable Immunoglobulin Gene Repertoire Biases, Stereotyped Antigen-Binding Sites and Recurrent Hypermutations in Certain Subsets

1934 Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab

1935 Prognostic Importance of Soluble Form IL-2 Receptor α (sIL-2Rα) and Its Relationship with Surface Expression of IL-2Rα of Lymphoma Cell in Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy: a Retrospective Analysis of 409 Cases

1936 Prognostic Significance of Circulating Epstein-Barr Virus (EBV) DNA in Non-Hodgkin's Lymphoma

1937 PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM)

1938 Expression of the B-Cell Stimulatory Factors BAFF and APRIL in Gastric MALT Lymphomas

1939 Association of Genetic Polymorphisms of Glutatione-S-Transferase Genes and Overall Response/Clinical Features in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab

1940 The Role of JAK3 mutations in Adult T-Cell Leukemia/Lymphoma

1941 A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma

1942 Diffuse Large B-Cell Lymphoma in the Very Elderly, a Study of Outcome in Patients Aged 80 and Older

1943 Identification of Genes Which Play a Crucial Role in C/EBPß Downstream Signalling in ALK+ ALCL Cell Lines

1944 High Risk of Hepatitis B Virus Reactivation in Isolated Anti-Hbc Positive Patients with B-Cell Lymphoma Receiving Rituximab Containing Chemotherapy

1945 T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis

1946 Predictors of Early Response to Single Agent Rituximab in Patients with Indolent Lymphoma

1947 IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom’s Macroglobulinemia

1948 High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT)

1949 Prediction of MHC Class I-Restricted Immunogenic Epitopes of B-Cell Receptors Indicates T Cell-Mediated Immunosurveillance of Malignant B Cell Clones

1950 Activation of T- and NK- Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin´s Lymphoma

1951 First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin’s Lymphoma (NHL)

1952 Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma

1953 CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas

1954 Impact of Socioeconomic Status & Race/Ethnicity On Survival in Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study

1955 Stimulation of B-Cell Mature Malignancies with the CpG-Oligonucleotide DSP30 and Interleukin-2 for Improved Detection of Chromosome Abnormalities

1956 Negative Interim FDG-PET Scan Is Predictive of Superior Outcome in T Cell Lymphoma

Clinical Results - Allogeneic Matched Related Donor Transplantation: Lymphoid Malignancies/Myeloma

49 Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis

50 Tandem Autologous-Allogeneic Nonmyeloablative Sibling Transplant in Relapsed Follicular Lymphoma Leads to Impressive Progression Free Survival with Minimal Toxicity

51 Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial

52 Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT

53 Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis

54 Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 – 2005

Lymphoma: Chemotherapy, excluding Pre-Clinical Models - PET Therapeutic Strategies and Special Populations

97 First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d’Etude Des Lymphomes De l’Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano  Linfomi (IIL)

98 Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab

99 Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP

100 Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial

101 Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d’Etude Des Lymphomes De l’Adulte

102 Non-Hodgkin Lymphoma in Adolescents: Experiences in 378 Adolescent NHL Patients Treated According to Pediatric NHL-BFM Protocols

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Uncommon Lymphomas and Supportive Care

103 Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors

104 Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

105 Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome

106 Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL)

107 Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens

108 First Line Antiviral Therapy Significantly Improves Survival of Patients with Acute, Chronic and Smoldering ATL: a Worldwide Meta-Analysis

Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Clinicopathological Correlations in Non-Hodgkin Lymphoma

133 HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy

134 Follicular PD-1+ Lymphocytes in the Tumor Microenvironment Are An Independent Prognostic Factor in Follicular Lymphoma

135 Prospective Measurement of EBV-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK/T-Cell Lymphoma, Nasal Type

136 Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL)

137 PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

138 Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort

Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster II

2266 A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab

2267 Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial

2268 Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation

2269 Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 and Acute Graft-Versus-Host Disease After Allogeneic Hematopietic Cell Transplantation with Nonmyeloablative Conditioning

2270 Fludarabine-Associated Neurotoxicity After Hematopoietic Cell Transplantation (HCT): Clinical and Radiographic Features Predict Outcome

2271 High-Dose Melphalan Re-Induction with or without Stem Cell Support Prior to Myeloablative Allogeneic Stem Cell Transplantation in Patients with Advanced Relapsed or Refractory Acute Myeloid Leukemia

2272 Low Dose Subcutaneous Alemtuzumab and Prophylactic Donor Lymphocyte Infusion Results in Favorable Outcomes for High Risk Recipients of Unrelated Donor Allogeneic Transplants

2273 Optimization of Fludarabine + Melphalan Conditioning for Marrow Transplantation From Unrelated Donors for Patients with Hematopoietic Malignancies: A Prospective Dose-Finding Trial Using Modified Continual Reassessment Method

2274 Pegfilgrastim Accelerates Neutrophil Engraftment, Reduces the Number of Neutropenic and Hospitalization Days and the Use of Antibiotics After Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma and Lymphoma. A Phase II Study and Comparison with a Filgrastim Treated Historical Cohort

2275 Pegfilgrastim Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay

2276 Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration

2277 Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization

2278 The Effect of Obesity On Outcome of Unrelated Cord Blood Transplant in Children with Malignant Diseases

2279 The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients

2280 The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation

Clinical Results - Allogeneic Matched Related Donor Transplantation Poster II

2281 A Markov Decision Analysis of Post-Remission Strategies in 2029 Patients with AML in First Remission (CR1): Should We Perform Allogeneic Hematopoietic Cell Transplantation in CR1?

2282 A Reduced Rate of Leukaemia Relapse  After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but Not Other Haematological Malignancies Is Associated with Donor KIR Genes 2DL5A, 2DS1 and 3DS1

2283 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis

2284 Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients

2285 First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma

2286 High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry

2287 Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)

2288 Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan

2289 Proportion of Adult AML Patient Population Receiving Allogeneic Stem Cell Transplantation and Long-Term Outcome: Real World Data From the Swedish National Acute Leukemia Registry

2290 Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia

Clinical Results - Autologous Transplantation Poster II

2309 A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma

2310 Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

2311 Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study

2312 Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial

2313 Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma

2314 High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Primary Therapy of Advanced Follicular Lymphoma in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

2315 Higher Incidence of Relapse with Higher Doses of CD34+ Cells From Leukapheresis Products Infused in Adults with Acute Myelocytic Leukemia Autografted During the First Remission

2316 Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL)

2317 Reduced Intensity Conditioning Regimens in Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis patients

2318 Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis

2319 Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts:  Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization

2320 Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group "Myelome-Autogreffe", Caen, Creteil, Limoges, Paris, Strasbourg, France

 2321 Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia

2322 Two Cycles of PAD Combination (PS-341/ Bortezomib, Adriamycin and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation (AHCT) in Newly Diagnosed Multiple Myeloma (MM) Patients

2323 Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL)

Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster II

2679 Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany)

2680 A Non-Radiation-Containing, Intermediate-Dose Methotrexate (MTX) Regimen Resulted in Favorable Survival without Progression of Dementia in Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL)

2681 Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma: A Pooled Analysis

2682 CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL)

2683 Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement

2684 Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin’s Lymphoma (DLBCL): Final Results and Long Term Follow-up

2685 Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia

2686 Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)

 2687 How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial)

2688 Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma

2689 Long-Term Outcomes of Patients with Newly Diagnosed NK/T-Cell Lymphoma Treated by EPOCH Regimen

2690 Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration

2691 Outcome of Second Line Therapy for Pediatric Patients with Hodgkin Lymphoma Who Relapse Following ABVD Based Therapy

2692 Pegylated Liposomal Doxobubicin (PLD) Can Be Escalated in a Dose-Dense, 14 Day CDOP-Rituximab Regimen without Affecting Relative Dose Intensity (RDI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Are Elderly or Have Compromised Cardiac Status

2693 Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052

2694 Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with  Primary Central  Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial

2695 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters

2696 Post-Chemotherapy Brain Irradiation in Primary CNS Lymphomas: Impact on Survival of Different Fields and Doses

2697 Primary Testicular Diffuse Large B-Cell Lymphoma, M.D. Anderson Cancer Center Experience

2698 Risk Factors for Early Transformation of Follicular Lymphoma (FL): Report From the National LymphoCare Study (NLCS)

2699 Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Who Had Received Prior Stem Cell Transplant

2700 The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis

2701 Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group

2702 Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center

2703 Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): A Valuable Tool for Risk Stratification in Mantle Cell Lymphoma

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II

2704 Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma

2705 Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease

2706 Enhancing Natural Killer (NK) Cell Mediated Killing of Non-Hodgkin’s Lymphoma

2707 GA101-Coated Target Cells Are More Effective Than Rituximab-Coated Target Cells at Activating NK Cells When Complement Is Present

2708 Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms

2709 In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer

2710 Mitochondrial-Mediated Apoptosis in Lymphoma by the Diterpenoid Lactone Andrographolide (Andro), the Active Component of Andrographolis Paniculata

2711 Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia

2712 Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma

2713 PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells

2714 The Combination of Arsenic Trioxide and Interferon-Alpha Eradicates Leukemia Initiating Cells in TAX-Driven Murine Adult T Cell Leukemia/Lymphoma

2715 The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies

2716 Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts

2717 Treatment with the CXCR4 Antagonist AMD3100 Enhances Antibody Mediated Killing in Disseminated Lymphoma Models

2718 YM155, a Novel Survivin Suppressant, Improves the Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster II

2719 A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma

2720 A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients

2721 CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma

2722 Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy

2723 Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 µg/m²/d of BiTE® Antibody Blinatumomab

2724 Molecular Remission after Induction Chemo- Immunotherapy and Rituximab Maintenance in Previously Untreated Follicular Lymphoma

2725 Multicenter Phase II Study of the CyclOBEAP Plus Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers

2726 Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma

2727 Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom’s Macroglobulinemia

2728 Response Is Seen to Conjugate Vaccine but Not to Polysaccharide Vaccine Twelve Months After Rituximab

2729 Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group

2730 Sustained, Durable Responses with Alemtuzumab in Refractory Angioimmunoblastic T-Cell Lymphoma

2731 The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study

2732 Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin’s Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study

Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster II

2918 Risk of Hepatitis B Virus (HBV) Reactivation and Efficacy of Antiviral Preemptive Therapy in Malignant Lymphoma Patients Who Have Resolved HBV

2919 Cerebrospinal Fluid Flow Cytometry Analysis in Newly Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal Disease: Result of a Multicentric Prospective Italian Study

2920 Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

2921 Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre

2922 Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)

2923 The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab

2924 The Immunohistochemical Pattern of Indoleamine 2,3-Dioxygenase in Tumor Tissue Indicates the Prognosis of Patients with Diffuse Large B-Cell Lymphoma

2925 Nuclear Expression of the Sox 11 Transcription Factor in Mantle Cell Lymphoma, and Cytoplasmic Expression in Follicular Lymphoma and Multiple Myeloma: Pathogenetic Implications

2926 Waldenstrom's Macroglobulinemia: A SEER Database Review From 1981-2005

2927 Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL

2928 Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era

2929 MicroRNAs Are Differentially Expressed in Primary Central Nervous (CNS) and Nodal Diffuse Large B-Cell Lymphomas

2930 ''CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.''

2931 The 18F-FDG SUVmax Reduction After Two Cycles of R-CHOP Regimen Predicts Progression Free Survival of Patients with Diffuse Large B-Cell Lymphoma

2932 P52 Activation in Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorders without BAFF-R Expression

2933 Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial

2934 Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenstrom’s Macroglobulinemia Patients

2935 Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom’s Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment

2936 Integrative Analysis of MicroRNA and Gene Expression Profiling Contributes to Understand Mantle Cell Lymphoma Pathogenesis

2937 The Type of Enteropathy Is a Prognostic Factor in Enteropathy-Associated T-Cell Lymphoma

2938 Two Distinct Syndromes of Lymphoma-Associated Amyloidosis: Findings From a Case Series

2939 SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN’S LYMPHOMA

2940 Central Nervous System Involvement in Primary Nasal Lymphoma

2941 PTEN Regulates SYK-Directed AKT Activation in MCL

2942 Detection of LMO2 in Normal Human Tissues and Haematopoietic and Non-Haematopoietic Tumours by a Newly Developed Rabbit Monoclonal Antibody

2943 Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL 

2944 Minimal Disseminated Disease Is An Indipendent Poor Prognosis Marker Among High Risk Burkitt’s Lymphoma Patients 

2945 High-Throughput Analysis of Antigen Recognition by the B Cell Receptors of Malignant Lymphomas with High-Density Protein Microarrays

2946 Involvement of Ets Factor Spi-B, E Protein E2-2, and Id2 in Waldenström’s Macroglobulinemia

2947 "Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)."

2948 Detailed Phenotypic Characterization of T-Cell Populations in Reactive, Normal and Follicular Lymphoma Nodes: Elevation of Follicular B Helper T-Cell Subsets in Follicular Lymphoma

2949 Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom’s Macroglobulinemia

2950 Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling

2951 Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma

2952 Patients with Waldenstrom’s Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin

Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols

193 Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study

194 Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a Retrospective Study of 629 Patients From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

195 Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey

196 Reduced-Intensity Conditioning with FBA/FBAA Regimen Is Feasible for Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML): Interim Results of a Multicenter Clinical Trial in China

197 Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes

198 Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols

313 NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of γδ T-Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent

314 Epstein Barr Virus Micrornas Repress BCL6 Expression in Diffuse Large B Cell Lymphoma

315 Targeting of SMAD5 Links MicroRNA-155 to the TGFβ Pathway and Lymphomagenesis

316 HGAL, a Lymphoma Prognostic Biomarker, Regulates Lymphocyte and Lymphoma Cell Motility by Modulation of RhoA Signaling Pathway

317 Evidence for Antigen-Driven Development of Molecularly Classified Burkitt Lymphomas

318 Non Germinal-Center B Cell Like Diffuse Large B Cell Lymphoma Results From Repeated Activation of IgM B Cells That Resist Class-Switching

Experimental Transplantation - Basic Biology, Immune Function, and Engraftment: Insights Into Mechanisms of Stem Cell Mobilization, Homing and Expansion

367 Mobilization Studies in Complement-Deficient Mice Reveal That AMD3100 Mobilization Depends On Complement Cascade Activation and Suggest Involvement of “Membrane Attack Complex - MAC” in Egress of Hematopoietic Stem/Progenitor Cells

368 Plerixafor (Mozobil®) Selectively Enhances Donor Hematopoietic Cell Engraftment

369 Human Umbilical Cord Blood Stem Cell Function Is Augmented by Exposure to Prostaglandin E2

370 In Vivo Treatment with Chromatin Modifying Agents Dramatically Increases Hematopoietic Stem Cell Numbers

371 Granulocyte-Derived Cationic Peptides (GDCPs) Present in Leucophoresis Products Enhance Homing of Hematopoietic Stem Cells (HSCs) to SDF-1 Gradient; Potential Implications for Accelerated Recovery of Hematopoiesis After Transplantation of Mobilized Peripheral Blood Stem Cells (PBSC)

372 Use of the CD26 Inhibitor Diprotin A (Ile-Pro-Ile) to Increase Mobilized Peripheral Blood Mononuclear Cell Adhesion and Migration

Lymphoma: Chemotherapy, excluding Pre-Clinical Models - Non-Hodgkin Lymphoma: Therapy

403 R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma Outcomes Database Project

404 Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High – Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

405 Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)

406 R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study

407 Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II  Study by the NCIC Clinical Trials Group

408 R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines

Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Genetic Factors in Lymphoma

439 Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma

440 Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma

441 Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma

442 The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

443 MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras

444 SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL)

Clinical Care - Acute and Chronic GVHD, Infectious Complications and Immune Reconstitution of Transplantation: Immunology of Acute and Chronic Graft-versus-Host Disease

511 Selecting Haploidentical Transplant Donors for Deploying Optimal NK Cell Allotherapy

512 Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe Gvhd

513 Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation

514 Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host Disease

515 Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations

516 Low Absolute CD4 Central Memory Count On Day 30 Is Associated with An Increased Incidence of Chronic Graft-Versus-Host Disease

Clinical Care, Recurrence, Secondary Neoplasia and Late Complications After Transplantation II

517 Population-Based Analysis of Late Cardiovascular Morbidity and Hospitalizations After Hematopoietic Cell Transplantation

518 Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning

519 Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies  Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients

520 Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders

521 Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT)

522 Development of Psycho-Intellectual Performances of Transplanted Sickle Cell Disease Patients: a Prospective Study From Pre-Transplant Period to 5 Years After HSCT

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: New Targets in the Treatment of Lymphomas

583 IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study

584 Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive’ Lymphoma

585 Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

586 A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine:  Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma

587 A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom’s Macroglobulinemia

588 Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity

Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Diffuse Large B-cell lymphoma: Biology and Prognosis

619 ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures

620 Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue:  A Study From the Lymphoma and Leukemia Molecular Profiling Project

621 Molecular Profiling Identifies Plasmablasts as the Cells of Origin of Activated Diffuse Large B Cell Lymphoma

622 Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions

623 Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han’s Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy

624 MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Clinical Results - Alternative Donor Transplantation II

661 Re-Exposure of Cord Blood (CB) to Non-Inherited Maternal HLA Antigens (NIMA) Improves Transplant Outcome in Patients (pts) with Hematologic Malignancies and May Reduce Relapse

662 Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors

663 Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study

664 Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies

665 Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML

666 Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological Malignancies: Results in 46 Patients

Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Indolent Non-Hodgkin's Lymphoma: Biology

757 Follicular Lymphoma Cell Niche: Identification of a Preeminent IL-4-Dependent TFH- B Cell Axis

758 Increased Proportions of CD39+ Infiltrating T-Cells Contribute to Adenosine Mediated T-Cell Hypo-Responsiveness within Human Follicular Lymphoma

759 A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling

760 Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome

761 The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom’s Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor

762 Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM

Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation Poster II

3304 A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis

3305 Allogeneic Stem Cell Transplantation (allo-SCT) for Secondary Acute Myeloid Leukemia (AML) Following Breast Carcinoma

3306 Antithymocyte Globuline Given as Part of the Conditioning Regimen Has No Impact On Lung Function at 1 Year After Transplantation

3307 Comparison of Outcomes Between 2-Year Survivors After Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

3308 Cryopreserved G-CSF Mobilized Donor Lymphocyte Infusion (DLI) without Withdrawal of Immunosuppression Is Safe and Highly Effective for Treating Isolated Poor Donor T-cell Chimerism Following Reduced Intensity Allogeneic Transplantation (RICT)

3309 Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT

3310 Donor Lymphocyte Infusions and Rituximab Are An Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced Intensity Allogeneic Stem Cell Transplantation

3311 Efficient Selection of WT1-Specific Donor Lymphocytes by Streptamer Technology

3312 Favorable Outcome and Quality of Life in Patients Surviving 5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

3313 Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT

3314 High Prevalence of Dapsone-Induced Oxidant Hemolysis in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase Deficiency

3315 Home Telemetric Monitoring of Pulmonary Function After Allogeneic Hematopoïetic Stem Cell Transplantation: Results of a Prospective Study Including 120 Patients

3316 Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia

3317 Immunological Intervention Triggered by Decreasing CD34+ Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

3318 Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation

3319 Incidence and Characterization of Taste Disturbances After Allogeneic or Autologous Hematopoietic Stem Cell Transplantation Using Myeloablative or Reduced-Intensity-Conditioning

3320 Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism

3321 Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase

3322 Low Vitamin D Levels After Allogeneic Hematopoietic Stem Cell Transplant

3323 Myeloablative Second Transplants Are Associated with High Non-Relapse Mortality  and Poorer Survival Than Non-Myeloablative Second Transplants

3324 Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes

3325 Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma

3326 Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD)

3327 Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation

3328 Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST)

3329 Total Body Irradiation (TBI) Increases Cardio-Metabolic Risk and Induces Carotid Vascular Stiffness in Survivors After Hematopoietic Cell Transplant (HCT) for Childhood Hematologic Malignancies

3330 Vaccinations Efficacy in Long Term Survivors After Allogeneic Stem Cell Transplantation: Implication of Repeat Vaccinations and Documenting Vaccination Efficacy

Clinical Results - Allogeneic Matched Related Donor Transplantation Poster III

3356 12 Years Experience in Peru with Related Allogeneic Stem Cell Transplantation (allo-sct) in Children with High Risk ALL

3357 90y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

3358 Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation

3359 Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up

3360 Autologous and Allogeneic Stem Cell Transplantation for Richter’s Transformation: A Retrospective Analysis From the Chronic Leukaemia Working Party and Lymphoma Working Party of the EBMT

3361 Bone Marrow Transplantation From HLA-Identical Sibling for Thalassemia

3362 Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion

3363 Comparison of Allogeneic Stem Cell Transplantation and Best Supportive Care in Elderly Patients with Advanced MDS

3364 Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT

3365 Estimating the Causal Effect of Some Exposure From Nonrandomized Studies: The Example of Reduced Intensity Conditioning (RIC) in Hematological Diseases

3366 First Line Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma (MCL)

3367 Graft Versus Host Disease Correlates with Increased Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas: Evidence of Graft Versus T-Cell Lymphoma Effect

3368 Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease

3369 Long-Term Complete Responses to Combination Therapies in Sézary Patients

3370 Long-Term Outcome of ATL Patients Who Underwent Reduced-Intensity Stem Cell Transplantation (RIST): Suggested Potent Graft-Versus-ATL and HTLV-1 Effects

3371 Prospective Phase II Study of Pre-Administration of Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®)  to Maximize Early T-Cell Chimerism Following Allogeneic Reduced Intensity Conditioning Transplant (RICT) through  Differential in-Vivo Depletion of Recipient Versus Donor T-Cells

3372 Retrospective Monocentric Study of Patients with Refractory Hodgkin Lymphoma: Allogeneic Stem Cell Transplantation (alloSCT) Compared to Conventional Treatment Using the Propensity Score Matching Method

3373 Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

3374 The Association of Fludarabin, Oral Busulfan and Thymoglobulin Prior to Matched-Related Allo-SCT Allows for High Long Term Outcome for Both Patients with Myeloid or Lymphoid Malignancies and Reveals the Impact of CD34+ Graft Cell Dose On Cgvhd and Outcome: Long Term Analysis of a Homogenous Cohort of 100 Consecutive Patients

3375 The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning  Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study

Clinical Results - Autologous Transplantation Poster III

3400 Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients

3401 Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis

3402 A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

3403 A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma

3404 An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide

3405 Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900

3406 Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes

3407 Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome

3408 Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group

3409 Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years)

3410 Febrile Neutropenia, Mucositis and Duration of Hospitalization Are Reduced After Pegfilgrastim Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Malignant Lymphopathies: Report of 683 PBSCTs From a Single Institution

3411 High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM)

3412 High Dose Cyclophosphamide (HD CY) without Hematopoietic Stem Cell Transplantation (HSCT)  in Refractory Severe Autoimmune Diseases: 11 Year Experience in Over 100 Patients

3413 Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers

3414 Interim Restaging FDG-PET/CT to Guide Use of High Dose Sequential Induction Therapy with Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (RDICEP) and Rituximab-Carmustine, Etoposide, Cytarabine, Melphalan (RBEAM) and Autologous Stem Cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

3415 Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies

3416 Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events

3417 Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

3418 Reapplication of High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation as Salvage Treatment for Patients with Relapsed or Refractory Multiple Myeloma – a Single Center Experience

3419 Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients

3420 Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy

3421 SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM)

3422 The Number of CD4+ T-Lymphocytes in the Autograft Correlates with Outcome After Autologous Stem-Cell Transplantation in Relapsed Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

3423 Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma

Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster III

3692 Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain

3693 A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

3694 Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study

3695 Phase I/II Study of Escalating Doses of Idarubicin Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma

3696 A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma

3697 Dose-Dense Weekly Rituximab and Standard CHOP Therapy in 123 Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma; Ganken Ariake Lymphoma Study Group Analysis

3698 Clinical Experience of Bendamustine Treatment for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry

3699 Identification of Potential Surrogate Endpoints in Randomized Clinical Trials of Aggressive Non-Hodgkin Lymphoma: Correlation of Complete Response, Time-to-Event and Overall Survival Data

3700 Phase I/II Study for the Effectivity of Rituximab, Gemcitabin and Oxaliplatin in Relapsed Indolent Lymphoma – An Interim Report

3701 Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor

3702 The Paediatric LMB Protocol Has High Curative Potential in Adults with Burkitt Lymphoma and High Proliferation DLBCL

3703 Gastric Diffuse Large B-Cell Lymphoma: Analyses of Prognostic Factors and Value of Pretreatment FDG-PET Scan

3704 Herpesviridae Viral Infections Following Chemotherapy in Patients with Lymphoma : Incidence, Risk Factors, and Prevention

3705 Escalated BEACOPP Versus ABVD-Like Chemotherapy for Hodgkin Lymphoma Patients: a Cochrane Review

3706 Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)

3707 Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

3708 Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas

3709 Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin

3710 "No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG)"

3711 Treating Hodgkin Lymphoma in HIV Positive Patients: a Comparative Analysis with the HIV Negative Population

3712 Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in Patients >65 Years

3713 A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay

3714 Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial

3715 Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL)

3716 Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study

3717 Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas

3718 The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated

3719 Enzastaurin in Patients with Non-Hodgkin Lymphomas: A Multicenter, Open-Label, Screening Study

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster III

3741 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma

3742 A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics

3743 A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Untreated Follicular Lymphoma (FL) Patients

3744 Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma

3745 Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies

3746 Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network

3747 Cyclophosphamide, Vincristine, Myocet and Prednisone ± Rituximab (COMP±R) Regimen Is Safe and Effective as First Line or Salvage Therapy in Elderly Non Hodgkin Lymphoma (NHL): Preliminary Data of Single Centre Experience

3748 Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL)

3749 Macrophage Polarization and Acquired Resistance to Rituximab in CNS Lymphoma

3750 Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom’s Macroglobulinemia

3751 Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma

3752 Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom’s Macroglobulinemia

3753 Pulmonary Infiltrates in NHL Patients Receiving Rituximab Combined with Chemotherapy: 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) Analysis and Clinical Correlates

3754 Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile

3755 Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL)

3756 Safety and Efficacy in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Early Results From Phase IIIb MAXIMA Trial

3757 Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies

3758 The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi

3759 Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma:  Median 10 Year Follow-up Results

Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster III

3919 Diagnostic and Therapeutic Implications of Expression and Phosphorylation of the Translation Regulatory Protein 4E-Binding Protein (BP)-1 in B-Cell Lymphomas and Reactive Lymphoid Tissues

3920 A Prospective Study Comparing CT, PET and PET/CT for Pre-Treatment Clinical Staging in Non-Hodgkin's and Hodgkin's Lymphoma

3921 Assessment of Circulating t(14;18)-Positive Cells in 4152 Individuals without Lymphoma Shows Association with Age and Gender, but Not with Smoking Status: Results From the Population-Based Study of  Health in Pomerania (SHIP)

3922 Bone Loss in Lymphoma Patients Receiving Frontline Therapy:  Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response

3923 Charlson Comorbidity Index Is An Independent Prognostic Factor Among Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

3924 Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma

3925 Distinct Interaction Networks of the MUM1/IRF4 in B- and T-Cell Lymphomas Identified by Tandem Mass Spectrometry

3926 EBV Infection and Altered Control of Apoptotic Pathways in Posttransplant Lymphoproliferative Disorders (PTLD)

3927 Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription

3928 Fine Needle Aspiration Biopsy with Flow Cytometry Is a Reliable Method for Defining Immunophenotype of Prognostic Value in T Lymphoblastic Lymphoma

3929 GATA-3 Promotes IL-10 Production and Is An Adverse Prognostic Factor in Peripheral T-Cell Lymphoma Unspecified (PTCL-U)

3930 Gene Expression Profiling Distinguishes Waldenstrom’s Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab

3931 Gene Expression Profiling Reveals Activation of Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis of Extranodal Nasal-Type NK/T Cell Lymphoma

3932 Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom’s Macroglobulinemia.

3933 Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma

3934 High Incidence of Hepatitis B or C Virus Infection in Lymphoma

3935 Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM

3936 Identification of Cyclin D1-Dependent Genes by Gene Expression Profiling in MCL Cell Lines and Primary Cases

3937 Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy

3938 Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis

3939 Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

3940 Junctional Adhesion Molecule C (JAM-C) Constitutes a New Marker for the Differential Diagnosis of B Cell Lymphomas

3941 Levels of Circulating Endothelial Cells and Endothelial Progenitors Correlate with Disease Status and Treatment Response in Human Lymphoma Subtypes of CLL and MCL

3942 Metalloproteinase Inhibitors Inhibit the Release of Soluble CD27 by Waldenström’s Macroglobulinemia Cells

3943 NIK and the Alternative NF-κB Pathway in Human Lymphomas

3944 Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL)

3945 Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis

3946 PIM as a Rational Target for B-Cell Lymphomas

3947 Post Transplant Lymphoproliferative Disorders (PTLD) After Lung Transplantation: Comparison of Patients with Early Versus Late Disease

3948 Pre-Treatment Serum Soluble Interleukin-2 Receptor Value Significantly Predicts Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

3949 Prognostic Impact of Mid-Treatment PET in Patients with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment PET

3950 Prognostic Significance of Promoter Methylation of Multiple Genes in Germinal Center Hyperplasia (GCH) and Lymphomas of Germinal Center Origin

3951 Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy

3952 Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM)

3953 Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma

3954 Sezary Syndrome Is a Malignancy of Central Memory T Cells with Skin Homing Properties, While Mycosis Fungoides Is a Malignancy of Skin Homing Effector Memory T Cells

3955 Simultaneous Detection of BCL2 Translocation and Copy Number Alteration Including Intrachromosomal Amplification in FL and DLBCL

3956 Single Nucleotide Polymorphisms (SNPs) of FCγRIIA and FCγRIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP with and without Rituximab: Results From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymhoma Study Group (DSHNHL)

3957 Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP

3958 The BBAP E3 Ligase Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response in Chemotherapy-Resistant Lymphomas

3959 The Overexpression of Enhancer of Zeste Homologue 2 Is Associated with Tumor Proliferation and Aggressive Behavior in Adult T-Cell Leukemia/Lymphoma

3960 Transformation of Indolent Small B-Cell Lymphoma to Histiocytic Sarcoma: Report of Two Cases with Molecular/Genetic Evidence of Clonal Relationship Between Two Morphologically and Immunophenotypically Distinctive Neoplasms

Clinical Results - Autologous Transplantation: Lymphoma and CLL

877 Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch

878 Autologous Stem Cell Transplantation (ASCT) in CLL. Results of a Phase III Randomized Multicenter Trial

879 Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial

880 Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma

881 Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study

882 A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?

Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments

919 Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial

920 Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma

921 Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts)

922 Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

923 Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant

924 Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Treatment of B-cell Lymphomas with Anti-CD20 Antibodies

931 "Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study"

932 90y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.  – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

933 Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study

934 A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease

935 Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma

936 Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a  Persistent Depletion of B Memory Cells

Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Non-Hodgkin's Lymphoma: Biology

967 Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study

968 Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors

969 Peripheral T-Cell Lymphoma. Molecular Heterogeneity Revealed by Integrative Genomic Analysis

970 Increased Immune Suppressive CD14+ hla-DRneg Circulating Monocytes Are Found in Aggressive Non-Hodgkin’s Lymphoma and Correlated with  Increased Arginase I Level

971 Aberrations of Genes Regulating NF Kappa B Pathway in B-Cell Malignant Lymphoma

972 The Role of ETV6/TEL in Hematopoiesis and Lymphoid Neoplasia